Navigation Links
Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
Date:9/17/2007

WALTHAM, Mass., Sept. 17 /PRNewswire-FirstCall/ -- Interleukin Genetics (Amex: ILI) today announced that its President and Chief Scientific Officer, Kenneth Kornman, DDS, PhD, will present at the Immunotoxicology V Conference on September 17-18, 2007 in Alexandria, VA. The conference will focus on innovative methods and applications for risk assessment in pharmaceutical development.

Among a group of presenters that includes industry regulators and some of the industry's leading researchers from major biotechnology and pharmaceutical companies, Dr. Kornman will be discussing multiple ways in which genetic variations in innate immunity may influence drug responses, and be relevant to drug development. As one example, he will discuss how certain genetic variations influence biological drug responses in the treatment of rheumatoid arthritis.

"Because of the critical role played by innate immunity in so many diseases, the potential for genetic variation to produce unexpected responses may be substantial," Dr. Kornman said. "We now know that genetic variations that regulate inflammatory responses make some individuals more responsive to a disease challenge but also more responsive to treatment. This information has great implications for drug development. We are currently using the genetic factors that control certain inflammatory responses to develop preventive and therapeutic products for genetically-targeted populations with common chronic diseases."

For more information on the conference or Interleukin please visit http://www.ilgenetics.com.

About Interleukin

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006 as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10- Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

For Interleukin Genetics:

Paul Voegelin (781) 398-0700

Additional Contacts for Media / Investors:

Erin Duggan (212) 445-8238, Weber Shandwick

Rich Tauberman (201) 964-2408, Financial Relations Board


'/>"/>
SOURCE Interleukin Genetics
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin court affirms damages in Innogenetics, Abbott patent case
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. Symposium examines the effect of race on genetics and disease
4. Siemens health services president calls IT benefits unassailable
5. Wisconsin IT association names Gee president, CEO
6. Merge Healthcare promotes Bowers to president
7. Quintessence Biosciences names new president
8. VanderSanden appointed president of AT&T Wisconsin
9. Merge president steps down in wake of shareholder suits
10. Milwaukees PointOne appoints new president and CEO
11. Cars.com president slated for Milwaukee event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/16/2017)... PARSIPPANY, N.J. (PRWEB) , ... July 16, 2017 ... ... products, laboratory equipment and analytical instruments announced the launch of its new line ... shakers are ideal for applications that require CO2 and humidity for optimal cell ...
(Date:7/14/2017)... ... July 14, 2017 , ... ... . Sonic Manufacturing Technologies has installed a solar system on its roof top. ... period,” the President of Sonic, Kenneth Raab stated. The company’s proud history of ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC Maine Standards ... US FDA 510 (k) clearance for use on Siemens Sysmex® CS-2500 System analyzers. ... D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample preparation, offers five ...
(Date:7/13/2017)... (PRWEB) , ... July 13, 2017 , ... Thousands of ... and August for the National Aeromodeling Championships (Nats). Pilots come to Muncie to compete ... to earn spots on US teams that participate in world championships. , RC Pylon ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):